Study of cedar pollen-specific s-IgA in pollinosis patients and healthy subjects

UMIN ID: UMIN000054636

Registered date:12/06/2024

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: pollinosis patients and subjects without allergic disease
• Date of first enrollment: 2024/06/14
• Target sample size: 40
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: Specific IgE antibody (cedar), nonspecific IgE antibody, SBP-specific IgG4, SBP-specific IgA, salivary secretory IgA (Total, SBP-specific)

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 65years-old
• Gender: Male and Female
• Exclude criteria: (1) Subjects who used steroid medication within 4 weeks prior to the test (2) Subjects who have difficulty restricting the use of medications that may affect nasal or eye discomfort for one month prior to the test (3) Subjects with bronchial asthma (4) Subjects who have received specific or non-specific immunotherapy in the past (5) Subjects who have problems or diseases involving bleeding in the oral cavity or who are undergoing dental treatment (6) Subjects who are judged to be unsuitable as subjects based on the answers to the background survey (7) Subjects who are judged as unsuitable for the study based on the results of the test (8) Subjects who are judged as unsuitable for the study by the principal investigator or the investigator for other reason

Related Information

• Primary Sponsor: EP Mediate Co., Ltd.
• Source(s) of Monetary Support: EPS Innovative Medicine (Japan) Co., Ltd.